May 16, 2024, 09:09
Kohei Shitara: Happy to report biomarkers in DESTINIY GC01 at Nature Medicine
Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan shared a post on X:
“Happy to report biomarkers in DESTINIY GC01 at Nature Medicine. Trastuzumab Deruxtecan (T-DXd), response high if ctDNA+ while still activity observed in negative patients. Response regardless of KRAS, HER2, PIK3CA mutation. Decrease response in other RTKamp+. HER2 loss or topo1mt on PD.”
Further Reading.
Source: Kohei Shitara/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 12, 2024, 23:10
Nov 12, 2024, 23:07
Nov 12, 2024, 22:58
Nov 12, 2024, 22:56
Nov 12, 2024, 22:50
Nov 12, 2024, 22:46
Nov 12, 2024, 22:43